Johnson & Johnson (JNJ): Dividends and Growth, All in One Place

As this aging bull market approaches its sixth year, protection against a correction is more important than ever. And you can find just that with Johnson & Johnson (JNJ), which is a reasonably valued play for just about everything — income, growth and defense. Risk-averse investors who want to stay in the game and go for growth should look to blue-chip companies with strong balance sheets that make brand-name products that consumers will continue to buy for generations. JNJ stock offers exactly that, as the global healthcare giant makes a wide variety of products that you’ll find in almost every consumer, physician and hospital supply cabinet.

With a market cap of $294.8 billion, a healthy dividend of 2.8% and a diversified portfolio of products that includes pharmaceuticals and medical supplies and devices, JNJ should continue to generate a great combination of income and appreciation — especially as economic recovery and Obamacare kick into higher gear in 2015. Johnson & Johnson’s consumer division produces familiar brands, including Tylenol, Neutrogena, Band-Aid and Listerine. JNJ’s medical devices and diagnostics division offers products used by healthcare providers in surgery, orthopedics, vision care, infection prevention and diagnostics.

Source: InvestorPlace

Related Articles:
- Dividend Growth Stocks With A Defined-Benefit Pension
- 7 Higher-Yielding Stocks With A Low Price To Book
- Don't Forget: Buy And Hold Is Not Buy And Forget
- 5 Stocks With Strong Dividend Growth Metrics
- Are Defense Stocks Good Defensive Stocks?